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Background: Levels of bone turnover markers (BTM) might be correlated with outcome in terms of skeletal-related events (SRE),
disease progression, and death in patients with bladder cancer (BC) and renal cell carcinoma (RCC) with bone metastases (BM).
We try to evaluate this possible correlation in patients who receive treatment with zoledronic acid (ZOL).
Methods: This observational, prospective, and multicenter study analysed BTM and clinical outcome in these patients. Serum
levels of bone alkaline phosphatase (BALP), procollagen type I amino-terminal propeptide (PINP), and beta-isomer of carboxy-
terminal telopeptide of type I collagen (b-CTX) were analysed.
Results: Patients with RCC who died or progressed had higher baseline b-CTX levels and those who experienced SRE during
follow-up showed high baseline BALP levels. In BC, a poor rate of survival was related with high baseline b-CTX and BALP levels,
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and new SRE with increased PINP levels. Cox univariate analysis showed that b-CTX levels were associated with higher mortality
and disease progression in RCC and higher mortality in BC. Bone alkaline phosphatase was associated with increased risk of
premature SRE appearance in RCC and death in BC.
Conclusion: Beta-isomer of carboxy-terminal telopeptide of type I collagen and BALP can be considered a complementary tool
for prediction of clinical outcomes in patients with BC and RCC with BM treated with ZOL.
The skeleton is the third most frequent site of tumour metastases,
behind lung and liver, and often the only site where metastases of
advanced solid tumours develop. Bone metastases (BM) are
observed in B80% of patients with advanced-stage malignant
tumours (Coleman et al, 2011). Thirty percent of patients with
renal cell carcinoma (RCC) are diagnosed with BM, and another
one-third of all patients will develop them throughout their disease
period, even after undergoing nephrectomy (Wood and Brown,
2012), meaning a majority of RCC patients will suffer BM at some
point of time. An estimated 40% of patients with bladder
carcinoma (BC) develop BM. As of diagnosis of BM, the median
survival of these patients is 12 months in RCC patients and 6–9
months in BC patients (Selvaggi and Scagliotti, 2005).
Bone metastases are associated with skeletal-related events
(SRE) such as pathological fractures, spinal cord compression,
severe bone pain, and hypercalcemia. Skeletal-related events can
dramatically impair quality of life, and therefore appropriate
management of cancer patients includes preservation of bone
health.
Balance between bone resorption and bone formation is
required for maintenance of bone metabolism. This equilibrium
is altered by BM, which can produce an increase not only in bone
formation but also in the destruction of bone. Bone metastases
from RCC and BC are lytic in nature, and the increase in bone
resorption is compensated by an increase in bone formation. Bone
metabolism can be reflected by bone turnover markers (BTM).
Previous studies have demonstrated that some BTM can alert to
the existence of BM (Zhao et al, 2011), but their correlation with
clinical outcomes is contradictory in different studies.
Several studies have demonstrated that bisphosphonates can
reduce SRE, resulting from BM, as they are bone-targeted agents
that inhibit osteoclast-mediated osteolysis and, hence, are currently
being recommended as standard therapy. Although several
bisphosphonates, which prevent SRE in patients with cancer and
BM are available, zoledronic acid (ZOL) is the first such agent with
proven efficacy for the prevention of SRE in patients with BM from
breast cancer, prostate cancer (PC), and other solid tumours (Saad
et al, 2012). Some authors had stated previously that ZOL could be
an effective treatment for reducing morbidity in advanced RCC
with BM (Zekri et al, 2001) and it has been proven in subsequent
studies (Lipton et al, 2003).
The aim of this work was to study levels of two bone formation
markers, bone alkaline phosphatase (BALP) and procollagen type I
amino-terminal propeptide (PINP), and one marker of bone
resorption, beta-isomer of carboxy-terminal telopeptide of type I
collagen (b-CTX), in a population of patients with RCC or BC and
bone metastases. The markers were studied at baseline and at 3, 6,
9, 12, 15, and 18 months after the beginning of treatment with
ZOL. The relationship of these markers with mortality, disease
progression, and SRE was also analysed.
MATERIALS AND METHODS
Study group. The TUGAMO study (‘Tumores UroGenitales
Avanzados y Marcadores O´seos’, or advanced urogenital tumours
and BTM) was performed in patients with PC, BC, and RCC with
bone metastases between 2009 and 2011. This article is a sub-
analysis of this study about BC and RCC patients. This was an
observational, prospective, and national multicenter study. The
study enroled patients X18 years of age with histologically
confirmed BC or RCC, and at least one diagnosed bone lesion
confirmed by scintigraphy. Patients were excluded from the study
if they presented with concomitant pathologies that could interfere
in the evaluation of BTM, such as bone metabolic disorders, Paget’s
disease of bone, hyperparathyroidism, thyroid abnormalities,
abnormal intestinal absorption, or hepatic or renal dysfunction.
Patients treated with bisphosphonates prior to their inclusion in
the study and those with dental infection or diagnosis of
osteonecrosis of the jaw were also excluded.
A follow-up of the patients was performed over 18 months.
Baseline values (visit 0, v0) were those obtained when a patient
initiated treatment with ZOL (Zometa, Novartis Pharma, Basel,
Switzerland), 4mg intravenous every 4 weeks for over 18 months.
Table 1. Baseline characteristics of RCC and BC patients
Baseline characteristics
RCC patients
(n¼39)
BC patients
(n¼34)
Mean age (years) 65.1 (43–82) 64.4 (44–77)
Sex (%)
Men 69.2 85.3
Women 30.8 14.7
ECOG performance status (%)
0 21.1 18.8
1 47.4 40.6
2 21.1 28.1
3 10.5 9.4
4 0 3.1
TNM stage (%)
I 0 6.7
II 5.7 16.7
III 34.3 6.7
IV 60 70
Previous surgery (%) 87.2 85.3
Mean time since bone metastases
diagnosed (months)
6.2 (0–59.1) 2.4 (0–34.6)
Previous SRE (%) 56.4 50
Analgesic treatment (%) 84.6 94.1
Antineoplasic treatment (%)
Chemotherapy 5.1 29.4
Antiangiogenic 61.5 2.9
mTOR inhibitors 20.5 0
Radiotherapy (%) 30.8 32.4
Abbreviations: BC¼bladder cancer; ECOG¼Eastern Cooperative Oncology Group;
mTOR¼mammalian target of rapamycin; RCC¼ renal cell carcinoma; SRE¼ skeletal-
related events; TNM¼ tumour, nodes, metastasis.
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In all cases, anticancer treatment could be changed as clinically
indicated throughout the course of the study. Data were collected
at v0, v1 (3 months), v2 (6 months), v3 (9 months), v4 (12 months),
v5 (15 months), and v6 (18 months). The definition of SRE was the
first of any of the following events: pathological fractures, severe
pain (which needed major analgesics, radiotherapy or surgery for
its treatment), hypercalcemia, and spinal cord compression.
Patients were also evaluated for disease progression by physical
examination, and Eastern Cooperative Oncology Group perfor-
mance status and pain score.
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Figure 1. Bone turnover marker evolution during follow-up in RCC patients. (A) Beta-isomer of carboxy-terminal telopeptide of collagen I (b-CTX);
(B) bone alkaline phosphatase (BALP); (C) procollagen type I amino-terminal propeptide (PINP). Values (y-axis) are shown as median and standard
deviation (BALP and PINP in mg l 1, and b-CTX in ngml 1). At x-axis, time of follow-up (months) and number of patients alive (n) are shown.
**Statistically significant differences with respect to baseline levels (Po0.05).
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This study was conducted in accordance with the guidelines of
the Declaration of Helsinki and Good Clinical Practice Guidelines
and the protocol was approved by the Ethics Committee of the
Hospital Clı´nico of Barcelona (Spain). Patients were given verbal
and written information and gave their informed consent to
participate in the study.
Analytical methods. Bone turnover markers were determined in
serum. Blood was collected between 0800 and 1000 hours in a
fasting state. Serum was kept at  80 1C until the moment of
markers determination.
Bone alkaline phosphatase was determined by ELISA (IDS,
Tyne & Wear, UK). Assay sensitivity was 0.7 mg l 1. The normal
range for healthy adult men was p15 UI l 1.
Procollagen type I amino-terminal propeptide was determined
by electrochemiluminescence (Elecsys, Roche, Mannheim,
Germany). Assay sensitivity was 5mg l 1. The normal range for
healthy adult men was p62 ngml 1.
Beta-isomer of carboxy-terminal telopeptide of type I collagen
was determined by electrochemiluminescence (Elecsys, Roche).
Assay sensitivity was 0.07 ngml 1. The normal range for healthy
adult men was p0.548 ngml 1.
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Figure 2. Bone turnover marker evolution during follow-up in BC patients. (A) Beta-isomer of carboxy-terminal telopeptide of collagen I (b-CTX);
(B) bone alkaline phosphatase (BALP); (C) procollagen type I amino-terminal propeptide (PINP). Values (y-axis) are shown as median and standard
deviation (BALP and PINP in mg l 1, and b-CTX in ngml 1). At x-axis, time of follow-up (months) and number of patients alive (n) are shown.
**Statistically significant differences with respect to baseline levels (Po0.05).
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Statistical analyses. Bone marker values were presented in terms
of mean, standard deviation, median, and quartiles. Absolute and
relative changes in bone markers as compared with baseline and
previous visit were assessed at each visit. Absolute changes were
summarised by mean and standard deviation, and their statistical
significance was assessed using the Wilcoxon test for paired
samples. Log transformation was performed for the relative
changes obtained, and these were summarised by geometric mean
and standard deviation. Statistical significance was assessed using
the Student’s t-test for paired samples. Receiver operating
characteristic (ROC) curves were used to assess the predictive
power of BTM levels for mortality, SRE, and progression.
Specifically, baseline levels and relative changes at 3 months from
baseline were taken as potential predictors. To assess the association
between these potential predictors and time to death, time to first SRE
and time to progression, a survival analysis was performed using the
Kaplan–Meier method and comparisons were performed using the
log-rank test. Finally, Cox regression models were fitted to quantify
the degree of association between potential predictors and mortality,
occurrence of SRE, and progression according to Kaplan–Meier
results. The models were summarised by hazard ratio estimate,
standard error, and 95% confidence interval for hazard ratio. Also, the
P-value obtained from hypothesis testing of the hazard ratio was
shown. The significance level was set at 0.05 for all tests.
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Figure 3. Kaplan–Meier analysis after the completion of treatment (18 months) with ZOL in RCC patients. (A) b-isomer of carboxy-terminal
telopeptide of collagen I (b-CTX) and overall survival. Stratification was performed using ‘normal or abnormal baseline marker values’ against
death. (B) b-CTX and overall survival. Stratification was performed using the cutoff point obtained from the ROC curves of ‘baseline values of
biomarkers at the beginning of the study’ against death. (C) b-CTX and disease progression. Stratification was performed using ‘normal or
abnormal baseline marker values’ against death. (D) b-CTX and disease progression. Stratification was performed using the cutoff point obtained
from the ROC curves of ‘baseline values of biomarkers at the beginning of the study’ against death. (E) Bone alkaline phosphatase (BALP) and new
SRE. Stratification was performed using the cutoff point obtained from the ROC curves of ‘baseline values of biomarkers at the beginning of the
study’ against death.
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Data were analysed with SAS, version 9.1.3. for Windows
(SAS Analytics, Madrid, Spain) and STATA, 4.0 for Windows
(StataCorp, London, UK).
RESULTS
Patient demographics. Thirty-nine patients with RCC and BM,
and thirty-four patients with BC and BM were included in the
study. Table 1 shows the demographics and baseline disease
characteristics of the patients studied.
Global survival, defined as the time between the beginning of the
18-month ZOL treatment and death, showed a median value of 10
months in RCC (2.4–17.5) and 8.9 months in BC (2.6–15.3). Thirty-
nine patients commenced RCC study and thirty-four patients began
BC study; out of them five and three patients completed it,
respectively. Losses of participants (RCC/BC) were due to death (21/
19), loss of informed consent (0/1), loss to follow-up (1/1), clinical
criteria (5/2), and others (e.g., change of address, renal insufficiency,
and progression—1/2). No patients presented with osteonecrosis of
the jaw or other severe secondary effects during follow-up.
Evolution of bone markers. The correlation among the markers
in RCC (b-CTX, PINP, and BALP) was strong at v1 and v2
(Po0.007), decreasing all values. In BC, b-CTX and BALP showed
a strong correlation at v1 (P¼ 0.02), BALP and PINP at v0
(P¼ 0.03), and b-CTX and PINP at v1, v2, and v3 (Po0.03).
Most patients with abnormal BTM levels showed a decrease in
levels after ZOL treatment. During the first six months, levels of
BTM tended to decrease significantly in both patient groups
(Figures 1 and 2).
In RCC, b-CTX was the marker which experienced the greatest
decrease and all patients showed normalisation in v1 (P¼ 0.007).
All patients remained normal during follow-up, except one patient
who got a change for the worse in v3 and died. Bone alkaline
phosphatase showed normalisation in v2 in 76.5% of patients
(P¼ 0.04), but six patients still showed abnormal values and one
patient got a change for the worse and died. Changes in PINP
values were not statistically significant in v1, with five patients with
abnormal values and four patients with worse values.
In BC, following ZOL treatment, 65% of patients exhibited
improved b-CTX and two patients got worse (P¼ 0.02) in v1. Bone
alkaline phosphatase had improved in 53% of patients at v1
(P¼ 0.01) and three patients remained with abnormal values.
Procollagen type I amino-terminal propeptide did not show
statistically significant changes. Only the three first visits were
analysed because the number of patients was too low at subsequent
visits. Levels of PINP and b-CTX at v2 decreased by 73 and 75%,
respectively (Po0.003). Bone alkaline phosphatase showed a
decrease of 44% at v1 (P¼ 0.02).
Bone markers as predictors of mortality risk, disease progres-
sion, and SRE appearance. Receiver operating characteristic
analyses were performed to evaluate BTM as predictors of mortality
risk, disease progression, and SRE appearance. Two different values
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Figure 4. Kaplan–Meier analysis after the completion of treatment (18 months) with ZOL in BC patients. (A) b-isomer of carboxy-terminal
telopeptide of collagen I (b-CTX) and overall survival. Stratification was performed using the cutoff point obtained from the ROC curves of
‘baseline values of biomarkers at the beginning of the study’ against death. (B) Bone alkaline phosphatase (BALP) and overall survival. Stratification
was performed using the cutoff point obtained from the ROC curves of ‘baseline values of biomarkers at the beginning of the study’ against death.
(C) Amino-terminal propeptide of procollagen I (PINP) and new SRE. Stratification was performed using relative changes between visit 0 and visit 1
(v1/v0) in relation to cutoff point obtained from the ROC curves against death.
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were used as a cutoff point: baseline BTM levels and respective
changes between v0 and v1 BTM levels. The sensitivity, specificity, and
positive and negative predictive values of each BTM in each disease
was found. The areas under the curve (AUC) were low for prediction
mortality risk in RCC patients (o0.6), but AUC was 0.769 for basal
b-CTX levels for prediction of disease progression and 0.719 for basal
PINP levels for prediction of SRE. For BC patients, AUC for basal
BALP levels was 0.801 for prediction of mortality risk and 0.716 for
prediction of SRE. The other AUC were too low.
Kaplan–Meier curves (KMc) were performed with four
categories:
(a) Baseline BTM normal or abnormal (defined as higher than the
upper limit of normality).
(b) Basal BTM ‘higher’ or ‘equal to or less than’ the cutoff
obtained in the ROC curves (ROC cutoff or ROC-CO).
(c) Relative changes between v0 and v1 (v1/v0) ‘higher than’ or
‘equal to or less than’ ROC-CO.
(d) Presence or absence of a normal BTM level at v1.
In RCC patients, KMc showed a significantly diminished
survival rate in patients with abnormal baseline b-CTX and in
those with higher b-CTX values than ROC-CO. Both groups also
exhibited an increase in disease progression. Baseline BALP levels
higher than ROC-CO showed a close relation with lesser time until
SRE appearance. Statistically significant KMc are shown in Figure 3.
Moreover, in BC patients, KMc showed a different survival rate in
patients with higher b-CTX and BALP levels using ROC-CO.
Patients whose PINP levels changed relatively between v0 and v1 had
a KMc that showed a lower time until new SRE appearance. No
significant differences were found in KMc regarding progression.
These statistically significant results are shown in Figure 4.
Univariate Cox regression was derived from the above-
mentioned KMc. Table 2 shows the hazard ratios for RCC patients
and Table 3 shows the hazard ratios for BC patients. In RCC,
higher b-CTX levels were related with death and a poor prognosis
for disease progression. Higher levels of BALP were associated with
premature SRE. In BC, higher b-CTX and BALP levels were also
related with death. The Cox regression regarding progression could
not be made because no significant differences were found in KMc.
Procollagen type I amino-terminal propeptide did not show being
associated with outcomes.
DISCUSSION
The usefulness of BTM as tool for the diagnosis of BM in many
types of cancers has been investigated previously (Coleman et al,
Table 2. Univariate Cox regression analysis of bone markers in renal cell carcinoma after 18 months of ZOL treatment
Variable HR 95% CI (HR) P-value
Death
Abnormal baseline b-CTX levels (40.548 ngml1) 2.834 1.076–7.465 0.035a
High baseline b-CTX levels (40.7 ngml1, ROC cutoff) 6.146 2.223–16.990 o0.001a
No normalisation of b-CTX levels in v1
b — — —
Abnormal baseline BALP levels (415UI l1) 1.226 0.475–3.165 0.674
High baseline BALP levels (417.9UI l1, ROC cutoff) 0.886 0.35–2.24 0.798
No normalisation of BALP levels in v1 2.283 0.54–9.662 0.262
Abnormal baseline PINP levels (462 ngml1) 1.644 0.655–4.123 0.29
High baseline PINP levels (4110.3 ngml1, ROC cutoff) 2.810 0.903–8.747 0.074
No normalisation of PINP levels in v1 2.511 0.614–10.275 0.2
Disease progression
Abnormal baseline b-CTX levels (40.548 ngml1) 4.036 1.364–11.938 0.012a
High baseline b-CTX levels (40.641 ngml1, ROC cutoff) 8.055 2.524–25.71 o0.001a
No normalisation of b-CTX levels in v1
b — — —
Abnormal baseline BALP levels (415UI l1) 1.028 0.355–2.976 0.96
High baseline BALP levels (412.4UI l1, ROC cutoff) 1.981 0.549–7.151 0.296
No normalisation of BALP levels in v1 1.097 0.227–5.315 0.908
Abnormal baseline PINP levels (462 ngml1) 1.681 0.589–4.793 0.331
High baseline PINP levels (487.5 ngml1, ROC cutoff) 1.723 0.599–4.957 0.312
No normalisation of PINP levels in v1 2.523 0.709–8.982 0.153
Skeletal-related events
Abnormal baseline b-CTX levels (40.548 ngml1) 0.881 0.268–2.897 0.834
High baseline b-CTX levels (40.157 ngml1, ROC cutoff) 2.992 0.386–23.211 0.294
No normalisation of b-CTX levels in v1
b — — —
Abnormal baseline BALP levels (415UI l1) 2.107 0.694–6.393 0.188
High baseline BALP levels (495.1UI l1, ROC cutoff) 3.634 1.071–12.323 0.038a
No normalisation of BALP levels in v1 3.050 0.699–13.303 0.138
Abnormal baseline PINP levels (462 ngml1) 3.155 0.91–10.934 0.070
High baseline PINP levels (453ngml 1, ROC cutoff) 3.253 0.886–11.939 0.075
No normalisation of PINP levels in v1 1.99 0.559–7.079 0.288
Abbreviations: BALP¼bone alkaline phosphatase; b-CTX¼beta-isomer of carboxy-terminal telopeptide of type I collagen; CI¼ confidence interval; HR¼ hazard ratio; PINP¼procollagen type
I amino-terminal propeptide; ROC¼ receiver operating characteristic; v1¼ visit 1; ZOL¼ zoledronic acid. Relative changes between v1 and v0 did not show statistically significant results, and
they are not shown.
aStatistically significant results.
bThere were no patients with abnormal levels in v1.
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2011; Huang and Ouyang, 2012). Many studies have analysed their
relationship with clinical outcomes (Mountzios et al, 2010; Kamiya
et al, 2010; Zaghloul et al, 2010; Coleman et al, 2011; Jung et al,
2011; Saad et al, 2012), as well as their clinical importance
(Coleman et al, 2010; Armstrong et al, 2012). However, only a few
articles have analysed the usefulness of BTM in RCC and less in
BC, and there is no consensus among these studies as to which
BTM is the ideal marker. Recently, the International Osteoporosis
Foundation and the International Federation of Clinical Chemistry
and Laboratory Medicine have recommended PINP and b-CTX as
reference markers in all clinical studies (Vasikaran et al, 2011), and
we have used them in our study previously to this recommenda-
tion. The utility of BTM as markers of the presence of BM before
their appearance in the bone scintigraphy has been taken up in
many studies (Zhao et al, 2011). In the case of RCC and BC, BTM
utility is more important because early bone metastatic lesions in
these tumours may not be easily detected by scintigraphy due to
their lytic nature (Wood and Brown, 2012). In one study (Kleipzig
et al, 2008), they found that PINP was a good predictor of BM in
patients with RCC. In two studies (Ramankulov et al, 2007, 2008),
these authors analysed osteopontin (a bone-related protein) and
serum amyloid A, finding that both were unspecific markers in
relation to the number or localisation of metastatic lesions
in patients with RCC. Other authors (Okamura et al, 2003) found
that ICTP (a telopeptide of collagen type I) can detect BM in
genitourinary cancers. In a study of BC patients (Zissimopoulos
et al, 2009), PICP (similar to PINP) showed a significant difference
between patients with or without BM. In spite of these results, in a
recent review (Huang and Ouyang, 2012) they concluded that,
currently, no BTM can predict occurrence of BM in the absence of
bone imaging techniques, and that more prospective trials are
needed to assess this possibility. We are currently unable to answer
this question, because all our patients were previously diagnosed
with BM. To date, no study has provided a definitive answer to this
question about BTM and premature diagnosis of BM in RCC.
In the current work, we have demonstrated that patients with RCC
and BM and elevated baseline b-CTX levels had a higher risk of death
and a higher estimated risk of disease progression than those patients
whose levels were normal or lower than ROC-CO. When baseline
BALP levels were higher than ROC-CO, the estimated risk of
premature SRE was also elevated. Procollagen type I amino-terminal
propeptide was not associated with analysed clinical outcomes.
No study has arrived at the same conclusions as these regarding
RCC. Some authors (Ramankulov et al, 2007, 2008) have found
that osteopontin, serum amyloid A, and presence of distant
metastases were independent survival predictors in RCC. Other
articles (Vermaat et al, 2010) found the same results about amyloid
A and added to that elevated levels of apolipoprotein-A2 and
transthyretin were associated with better prognosis. Other authors
(Kume et al, 2011) collected RCC cases and found an association
between total alkaline phosphatase and overall survival. Another
one (Jung et al, 2006) had found that osteoprotegerin was
predictive of cancer-specific survival in a multivariate model. In
a study with a variety of solid tumours, including RCC, a
multicenter study (Coleman et al, 2005) found that increased
values of BALP and NTX (amino-terminal telopeptide of collagen
I) were associated with increased risk of death, SRE, and disease
progression in patients with breast cancer, PC, myeloma,
Table 3. Univariate Cox regression analysis of bone markers in bladder cancer after 18 months of ZOL treatment
Variable HR 95% CI (HR) P-value
Death
Abnormal baseline b-CTX levels (40.548 ngml1) 2.062 0.732–5.813 0.171
High baseline b-CTX levels (40.9 ngml1, ROC cutoff) 3.672 1.353–9.967 0.010a
No normalisation of b-CTX levels in v1
b — — —
Abnormal baseline BALP levels (415UI l1) 0.963 0.321–2.888 0.946
High baseline BALP levels (445.9UI l1, ROC cutoff) 2.597 1.08–6.248 0.033a
No normalisation of BALP levels in v1
b — — —
Abnormal baseline PINP levels (462 ngml1) 1.096 0.367–3.273 0.869
High baseline PINP levels (4128.7 ngml1, ROC cutoff) 1.313 0.54–3.191 0.548
No normalisation of PINP levels in v1 0.963 0.225–4.13 0.96
Disease progression
This analysis was not made because Kaplan–Meier curves showed no
statistically significance and it did not comply with assumption of
proportional risk
— — —
Skeletal-related events
Abnormal baseline b-CTX levels (40.548 ngml1) 1.427 0.387–5.268 0.593
High baseline b-CTX levels (40.8 ngml1, ROC cutoff) 2.714 0.811–9.085 0.105
No normalisation of b-CTX levels in v1
b — — —
Abnormal baseline BALP levels (415UI l1) 0.408 0.076–2.178 0.294
High baseline BALP levels (419.9UI l1, ROC cutoff) 2.819 0.727–10.92 0.134
No normalisation of BALP levels in v1 — — —
Abnormal baseline PINP levels (462 ngml1) 1.764 0.389–7.993 0.461
High baseline PINP levels (4106.8 ngml1, ROC cutoff) 2.418 0.797–7.33 0.119
No normalisation of PINP levels in v1 1.136 0.267–4.837 0.863
Abbreviations: BALP¼bone alkaline phosphatase; b-CTX¼beta-isomer of carboxy-terminal telopeptide of type I collagen; CI¼ confidence interval; HR¼ hazard ratio; PINP¼procollagen type
I amino-terminal propeptide; ROC¼ receiver operating characteristic; v1¼ visit 1; ZOL¼ zoledronic acid. Relative changes between v1 and v0 did not show statistically significant results and they
are not shown.
aStatistically significant results.
bThere were no patients with abnormal levels in v1.
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non-small-cell lung cancer and other solid tumours, treated with
bisphosphonates. Similar results had been found by the
same authors about NTX in bisphosphonates naive patients
(Brown et al, 2005).
As for patients with BC, an increased risk of death was
associated with high baseline b-CTX and BALP levels. Only one
similar result has been found previously (Lo´pez-Carrizosa et al,
2010), but the lower number of patients (2) made the results of the
study unreliable. Other authors (Ang et al, 2005) had found a
relation between osteopontin levels and stage of disease previously.
Although the current study is limited by the small number of cases
in the study groups, this is the first report in the literature showing
a relationship between BTM, BC, and clinical outcome.
As in our study, other authors have found relationships between
different tumours, clinical outcomes, and b-CTX. In patients with
PC, increased BTM levels (especially PINP and ICTP, a resorption
marker) have been related with survival, disease progression, and
SRE (Jung et al, 2011). Other authors (Zhao et al, 2011) studied
patients with PC and lung- and breast carcinoma. According to
their data, b-CTX and BALP can be considered to be good markers
for detecting BM. In addition, high values of PINP were related
with poor rates of survival.
Procollagen type I amino-terminal propeptide did not show a
statistically significant relation in either of the two cancers in our
study. The findings in KMc about relation between progression
and relative changes in PINP values in BC are not corroborated to
Cox regression, and it can be explained for low number of patients
in this group. Further studies with more patients are necessary
to support our findings.
Other markers have been well established as prognostic factors
in RCC, such as Motzer criteria (haemoglobin, Karnowsky
performance status, time from diagnosis to treatment with
interferon-alpha, lactate dehydrogenase, and corrected serum
calcium) (Motzer et al, 2002) or Heng criteria (haemoglobin, time
from diagnosis to treatment with interferon-alpha, corrected serum
calcium, neutrophils and platelets number) (Heng et al, 2009). In
BC, Eastern Cooperative Oncology Group performance status and
the presence of visceral metastasis have been associated with
decreased survival (Bellmunt et al, 2002). The main limitation of
our study is the small sample size of each of the groups (39 RCC
and 34 BC), which are far too small to do multivariable analysis to
determine if the BTM are independently predictive of important
clinical outcomes when these known prognostic factors (Bellmunt
et al, 2002; Motzer et al, 2002; Heng et al, 2009), history of prior
SRE, other bone-associated markers, and treatment effects are
considered all together. Future studies will have to address this
point.
CONCLUSIONS
Beta-isomer of carboxy-terminal telopeptide of type I collagen and
BALP can be considered promising prognostic factors of clinical
outcome in patients with RCC and BC with BM treated with ZOL
and they can be one more tool to those existent previously.
Metastatic bone disease in RCC and BC may benefit from greater
focus than it has to date, and their use may bring about an
important advance in the management of these patients. More
studies in larger groups of patients are necessary for further
confirmatory research.
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